Chronic myeloid leukemia: Why does it evolve from chronic phase to blast transformation?

Frontiers in Bioscience

Volumn 11, Issue 1 P.1-446, 2006, Pages 198-208

  Mughal, Tariq I ^a   Goldman, John M ^b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b NONE

Author keywords

Blast Transformation; Chronic Myeloid Leukemia; Chronic Phase; Evolution; Review

Indexed keywords

EID: 32844461437     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/1791     Document Type: Review

References (95)

1. Nowell PC, DA Hungerford: A minute chromosome in human chronic granulocytic leukemia. Science 132, 1497 (1960)
2. Mughal TI, JM Goldman: Chronic myeloid leukaemia: STI571 magnifies the therapeutic dilemma. Eur J Cancer 37, 561-568 (2001)
3. Sawyers CL: Chronic myeloid leukemia. N Engl J Med 340, 1330-1338 (1999)
4. Rowley JD: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243, 290-293 (1973)
5. Goldman JM, JV Melo: Chronic myeloid leukemia - Advances in biology and new approaches to treatment. N Engl J Med 349, 1451-1464 (2003)
6. Melo JV: The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype (editorial). Blood 88, 2375-2384 (1996)
7. Pendergast AM, LA Quilliam, LD Cripe, CH Bassing, Z Dai, N Li, A Batzer, KM Rabun, CL Der, J Schlessinger: BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell 75, 175-185 (1993)
8. Pendergast AM, AJ Muller, MH Havlik, R Clark, F McCormick, ON Witte: BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner. Cell 66, 161-171, (1991)
9. McWhirter JR, DL Galasso, JY Wang: A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Mol Cell Biol 13, 7587-7597 (1993)
10. Melo JV, MWN Deininger: Biology of chronic myelogenous leukemia-signaling pathways of initiation and transformation. Hematol Oncol Clin N Am 18, 545-568 (2004)
11. Ravandi F, J Cortes, M Albitar, R Arlinghaus, JQ Guo, M Talpaz, H Kantarjian: Chronic myelogenous leukemia with p185 (BCR/ABL) expression: characteristics and clinical significance. Br J Haematol 107, 581-586 (1999)
12. Pane F, F Frigeri, M Sindona, L Luciano, F Ferrara, R Cimino, G Meloni, G Saglio, F Savatore, B Rotoli: Neutrophilic-chronic myeloid leukemia (CML-N): a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction) (comments). Blood 88, 2410-2414 (1999)
13. Eaves CJ, AC Eaves: Progenitor cell dynamics. In: Chronic myeloid leukemia: biology and treatment. Eds: Carella AM, Daley GQ, Eaves CJ, Goldman JM, Hehlmann R, Martin Dunitz, London, UK. 73-100 (2001)
14. Jamieson CHM, LE Ailles, SJ Dylla, M Muijtjens, C Jones, JL Zehnder, J Gotlib, K Li, MG Manz, A Keating, C Sawyers, IL Weissman: Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 351, 657-667 (2004)
15. Daley GQ: Chronic myeloid leukemia: Proving ground for cancer stem cells. Cell 119, 314-316 (2004)
16. Graham SM, HG Jorgensen, E Allan, C Pearson, MJ Alcorn, L Richmond, T Holyoake: Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99, 319-325 (2002)
17. Coulombel L, DK Kalousek, CJ Eaves, CM Gupta, AC Eaves: Long-term marrow culture reveals chromosomally normal hematopoietic progenitor cells in patients with Philadelphia chromosome positive chronic myelogenous leukemia. N Engl J Med 308, 1493-1498 (1983)
18. Carella AM, M Podesta, F Frassoni, MR Raffo, N Pollicardo, E Pungolino, R Vimercati, M Sessarego, C Parodi, C Rabitti: Collection of 'normal' blood repopulating cells during early hemopoietic recovery after intensive conventional chemotherapy in chronic myelogenous leukemia. Bone Marrow Transplant 12, 267-271 (1993)
19. Laurent E, M Talpaz, H Kantarjian, R Kurzrock: The BCR gene and the Philadelphia chromosome-positive leukemogenesis. Cancer Res 61, 2343-2355 (2001)
20. Maru Y, ON Witte: The BCR gene encodes a novel serine/threonine kinase activity within a single exon. Cell 67, 459-468 (1991)
21. Reuther GW, H Fu, LD Cripe, RJ Collier, AM Pendergast: Association of the protein kinases c-BCR and Bcr-Abl with proteins of the 14-3-3 family. Science 266, 129-133 (1994)
22. He Y, JA Wertheim, L Xu, JP Miller, FG Karnell, JK Choi, R Ren, WS Pear: The coiled-coil domain and Tyr 177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl. Blood 99, 2957-2968 (2002)
23. Smith KM, R Yacobi, RA van Etten: Autoinhibition of Bcr-Abl through its SH3 domain. Mol Cell 12, 27-37 (2003)
24. Chissoe SL, A Bodenteich, YF Wang, YP Wang, D Burian, SW Clifton, J Crabtree, A Freeman, K Iyer, L Jian: Sequence and analysis of the human ABL gene, the BCR gene, and regions involved in the Philadelphia chromosomal translocation. Genomics 27, 67-82 (1995)
25. Feller SM, B Knudsen, H Hanafusa: c-Abl kinase regulates the protein binding activity of c-Crk. EMBO J 13, 2341-2351 (1994)
26. Sattler M, R Salgia, K Okuda, N Uemura, MA Durstin, E Pisick, G Xu, J-L Li J-L, KV Prasad, JD Griffin: The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3′ kinase pathway. Oncogene 12, 839-846 (1996)
27. Kipreos ET, JY Wang: Cell cycle-regulated binding of c-Abl tyrosine kinase to DNA. Science 256, 383-385 (1992)
28. Wen ST, PK Jackson, RA van Etten: The cytostatic function of c-Abl is controlled by multiple nuclear localization signals and requires the p53 and Rb rumour suppressor gene products. EMBO J 15, 1583-1595 (1996)
29. Taagepera S, D McDonald, JE Loeb, LL Whitaker, AK McElroy, JY Wang, TJ Hope: Nuclear-cytoplasmic shuttling of c-ABL tyrosine kinase. Proc Natl Acad Sci, 95, 7457-7462 (1998)
30. Barila D, G Superti-Furga: An intramuscular SH3-domain interaction regulates c-Abl activity. Nat Genet, 18, 280-282 (1998)
31. Pluk H, K Dorey, G Superti-Furg. Autoinhibition of c-Abl. Cell, 108; 2: 247-259, 2002.
32. bcr/abl gene of the Philadelphia chromosome. Science 247, 824-830 (1990)
33. Elephanty AG, DC Hariharan, S Cory: Bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haematopoietic neoplasms in mice. EMBO J 9, 1069-1078 (1990)
34. Huntly BJ, AG Reid, AJ Bench, LJ Campbell, N Telford, P Shepherd, J Szer, HM Prince, P Turner, C Grace, EP Nacheva, AR Green: Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia. Blood 98, 1732-1738 (2001)
35. Deininger MW, JM Goldman, JV Melo: The molecular biology of chronic myeloid leukemia. Blood 96, 3343-3356 (2000)
36. Puil L, J Liu, G Gish, G Mbamalu, D Bowtell, PG Pelicci, R Arlinghaus, T Pawson: Bcr-Abl oncoproteins bind directly to activators of the Ras signaling pathway. EMBO J 13, 764-773 (1994)
37. Pelicci G, L Lanfrancone, AE Salcini, A Romano, S Mele, M Grazia-Borrello, O Segatto, PP Di Fiore, PG Pelicci: Constitutive phosphorylation of She proteins in human tumors. Oncogene 11, 899-907 (1995)
38. Oda T, C Heaney, JR Hagopian, K Okuda, JD Griffin, BJ Druker: Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. J Biol Chem 269, 22925-22928 (1994)
39. Bhat A, K Kolibaba, T Oda, S Ohno-Jones, C Heaney, BJ Druker: Interactions of CBL with BCR-ABL and CRKL in BCR-ABL transformed myeloid cells. J Biol Chem 272, 16170-16175 (1997)
40. Marais R, Y Light, HF Paterson, CJ Marshall: Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation. EMBO J 14, 3136-3146 (1995)
41. Skorski T, P Kanakaraj, M Nieborowska-Skorska, MZ Ratajczak, SC Wen, G Zon, AM Gewirtz, B Perussia, B Calabretta: Phospatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood 86, 726-736 (1995)
42. Skorski T, A Bellacosa, M Nieborowska-Skorska, M Majewski, R Martinez, JK Choi, R Trotta, P Wlodarski, D Perrotti, TO Chan, MA Wasik, PN Tsichlis, B Calabretta: Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J 16, 6151-6161 (1997)
43. Jonuleit T, H van der Kuip, C Miething, H Michels, M Hallek, J Duyster, WE Aulitzky: Bcr-Abl kinase down-regulates cyclin-dependent kinase inhibitor p27 in human and murine cell lines. Blood 96, 1933-1939 (2000)
44. Franke TF, DR Kaplan, LC Cantley: PI3K: downstream AKTion blocks apoptosis. Cell 88, 435-437 (1997)
45. Komatsu N, T Watanabe, M Uchida, M Mori, K Kirito, S Kikuchi, Q Liu, T Tauchi, K Miyazawa, H Endo, T Nagai, K Ozawa: A member of the Forkhead transcription factor FKHRL1 is a downstream effector of STI571-induced cell cycle arrest in BCR-ABL-expressing cells. J Biol Chem 278, 6411-6419 (2003)
46. Shuai K, J Halpern, J ten Hoeve, X Rao, CL Sawyers: Constitutive activation of STAT5 by the BCDR/ABL oncogene in chronic myelogenous leukemia. Oncogene 13, 247-254 (1996)
47. Ilaria RL, RA van Etten: p210 and p190 (BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem 271, 31704-31710 (1996)
48. Frank DA, L Varticovski: BCR/ABL leads to the constitutive activation of STAT proteins and shares an epitope with tyrosine phosphorylated STAT. Leukemia 10, 1724-1730 (1996)
49. Klejman A, SJ Schreiner, M Nieborowska-Skorska, A Slupianek, M Wilson, TE Smithgall, T Skorski: The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells. EMBO J 21, 5766-5774 (2002)
50. Horita M, EJ Andreu, A Benito, C Arbona, C Sanz, I Benet, F Prosper, JL Fernandez-Luna: Blockade of the BCR/ABL kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transduce and activator of transcription 5-dependent expression of Bcl-XL. J Exp Med 191, 977-984 (2000)
51. Nieborowska-Skorska M, G Hoser, P Kossev, P Kossev, MA Wasik, T Skorski: Complementary functions of the anti-apoptotic protein Al and serine/threonine kinase pim-1 in the BCR/ABL-mediated leukemogenesis. Blood 99, 4531-4539 (2002)
52. James C, V Ugo, J-P Le Couedic, J Staerk, F Delhommeau, C Lacout, L Garcon, H Raslova, R Berger, A Bennaceur-Griscelli, JL Villeval, SN Constantinescu, N Casadevall, W Vainchenker: A unique clonal JAK2 mutation leading to constitutive signalling causes polycythemia vera. Nature doi:10.1038/nature03546 (2005)
53. Goldman JM: A unifying mutation in chronic myeloproliferative disorders. N Engl J Med 352, 1744-1746 (2005)
54. Menssen A, H Hermeking: Characterization of the c-MYC- regulated transcriptome by SAGE: identification and analysis of c-MYC target genes. Proc Natl Acad Sci 99, 6274-6279 (2002)
55. Sawyers CL, W Callahan, ON Witte: Dominant negative MYC blocks transformation by ABL oncogenes. Cell 70, 901-910 (1992)
56. Afar DE, A Goga, J McLaughlin, ON Witte, CL Sawyers: Differential complementation of Bcr-Abl point mutations with c-Myc. Science 264, 424-426 (1994)
57. Xie S, Y Wang, J Liu, T Sun, MB Wilson, TE Smithgall, RB Arlinghaus: Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation. Oncogene 20, 6188-6195 (2005)
58. Daley GQ, D Baltimore: Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific p21bcr/abl protein. Proc Natl Acad Sci 85, 9312-9316 (1988)
59. Bedi A, BA Zehnbauer, JP Barber, SJ Sharkis, RJ Jones: Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood 83, 2038-2044 (1994)
60. Amarante-Mendes GP, KC Naekyung, L Liu, Y Huang, CL Perkins, DR Green, K Bhalla: Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3. Blood 91, 1700-1705 (1998)
61. Amos TA, JL Lewis, FH Grand, RP Gooding, JM Goldman, MY Gordon: Apoptosis in chronic myeloid leukaemia: normal; responses by progenitor cells to growth factor deprivation, X-irradiation and glucocorticoids. Br J Haematol 91, 387-393 (1995)
62. Wang HG, Rapp UR, Reed JC: Bcl-2 targets the protein kinase Raf-1 to mitochondria. Cell 87, 629-638 (1996)
63. Burchert A, D Cai, L Hofbauer, MKR Samuelsson, EP Slater, J Duyster, M Ritter, A Hochhaus, R Muller, M Eilers, M Schmidt, A Neubauer: Interferon consensus sequence binding protein (ICSBP, IRF-8) antagonizes BCR/ABL and down-regulates bcl-2. Blood 103, 3480-3489 (2004)
64. Lange T, DW Niederwieser, MW Deininger: Residual disease in chronic myeloid leukemia after induction of molecular remission. N Engl J Med 349, 1483-1484 (2003)
65. Mughal TI, A Yong, RM Szydlo, F Dazzi, E Olavarria, F van Rhee, J Kaeda, NCP Cross, C Craddock, E Kanfer, J Apperley, JM Goldman: The probability of long-term leukaemia-free survival for patients in molecular remission 5 years after allogeneic stem cell transplantation for chronic myeloid leukaemia in chronic phase. Br J Haematol 115, 569-574 (2001)
66. Dai Z, RC Quackenbush, KD Courtney, M Grove, D Cortez, GW Reuther, AM Pendergast: Oncogenic Abl and Src tyrosine kinases elicit the ubiquitin-dependent degradation of target proteins through a RAS-independent pathway. Genes Dev 12, 1415-1424 (1998)
67. Biernaux C, M Loos, A Sels, G Huez, P Stryckmans: Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood 86, 3118-3122 (1995)
68. Bose S, M Deininger, TJ Gora, JM Goldman, JV Melo: The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood 92, 3362-3367 (1998)
69. Blick M, P Romero, M Talpaz, R Kuzrock, M Shtalrid, B Andersson, J Truijillo, M Beran, J Gutterman: Molecular characteristics of chronic myelogenous leukemia in blast crisis. Cancer Genet Cytogenet 27, 349-356 (1987)
70. Schutte J, B Opalka, R Becher, W Bardenheuer, S Szymanski, A Lux, S Seeber: Analysis of the p53 gene in patients with isochromosome 17q and Ph-positive or - negative myeloid leukemia Leuk Res 17, 533-539 (1983)
71. Jennings BH, KI Mills: C-myc locus amplification and the acquistion of trisomy 8 in the evolution of chronic myeloid leukemia. Leuk Res 22, 849-903 (1998)
72. Sawyers CL, W Callahan, ON Witte: Dominant negative MYC blocks transformation by ABL oncogenes. Cell 70, 901-910 (1992)
73. bcr/abl tyrosine kinase. Proc Natl Acad Sci 99, 13137-13142 (1996)
74. bcr/abl-expressing hematopoietic cells: a transgenic study for blast crisis of human CML. Blood 95, 1144-1150 (2000)
75. Beck Z, A Kiss, FD Toth, J Szabo, A Bacsi, E Balogh, A Borbely, B Telek, E Kovacs, E Olah, K Rak: Alterations of p53 and RB genes and the evolution of the accelerated phase of chronic myeloid leukemia. Leuk Lymphoma 38, 587-597 (2000)
76. Rabbitts TH, K Bucher, G Chung, G Grutz, A Warren, Y Yamada: The effect of chromosomal translocations in acute leukemias: the LMO2 paradigm in transcription and development. Cancer Res 59 (7 Suppl), 1794s-1798s (1999)
77. Koschmieder S, B Gottgens, P Zhang, J Iwasaki-Arai, K Akashi, JL Kutok, T Dayaram, K Geary, AR Green, DG Tenen, CS Huettner: Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cell in rransgenic model of BCR-ABL leukemogenesis. Blood 105, 324-334 (2005)
78. Clarke, MF: Chronic myelogenous leukemia - Identifying the hydra's heads. N Engl J Med 351, 634-637 (2004)
79. Shet AS, BN Jahagirder, CM Verfaillie: Chronic myelogenous leukemia: mechanisms underlying progression. Leukemia 16, 1402-1411 (2002)
80. Calabretta B, D Perrotti: The biology of CML blast crisis. Blood 11, 4010-4022 (2004)
81. Dierov J, R Dierova, M Carroll: BCR/ABL translocates to the nucleus and disrupts an ATR-dependent intra-S phase checkpoint. Cancer Cell 5, 275-285 (2004)
82. CS. Blood 97, 2084-2090 (2001)
83. Gottlieb TM, SP Jackson: The DNA-dependent protein kinase: requirements for DNA ends and association with Ku antigen. Cell 72, 131-142 (1993)
84. Deutsch E, S Jarrousse, D Buet, A Dugray, M-L Bonnet, M-C Vozenin-Brotons, F Guilhot, AG Turhan, J Feunteun, J Bourhis: Downregulation of BRCA1 in BCR/ABL-expressing hematopoietic cells. Blood 101, 4583-4588 (2003)
85. Jasin M: Homologous repair of DNA damage and tumorigenesis: the BRCA connection. Oncogene 21, 8981-8983 (2002)
86. Slupianek A, C Schmutte, G Tombline, M Nieborowska-Skorska, G Hoser, MO Nowicki, AJ Pierce, R Fishel, T Skorski: BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance. Mol Cell 8, 795-806 (2001)
87. Hernández-Boluda JC, F Cervantes, D Colomer, MC Vela, D Costa, MF Paz, M Esteller, E Montserrat: Genomic p16 abnormalities in the progression of chronic myeloid leukemia into blast crisis: a sequential study in 42 patients. Exp Hematol 31, 204-210 (2003)
88. Serrano M, H Lee, L Chin, C Cordon-Cardo, D Beach, RA DePinho: Role of the INK4a locus in tumor suppression and cell mortality. Cell 85, 27-37 (1996)
89. Donato NJ, JY Wu, J Stapley, G Gallick, R Arlinghaus, M Talpaz: BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to imatinib. Blood 101, 690-698 (2003)
90. Ptasznik A, Y Nakata, A Kalota, SG Emerson, AM Gewirtz: Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug resistant, BCR-ABL1(+) leukemia cells. Nature Medicine 10, 1187-1189 (2004)
91. O'Brien SG, F Guilhot, RA Larson, I Gathmann, M Baccarani, F Cervantes, JJ Cornelissen, T Fischer, A Hochhaus, T Hughes, K Lechner, JL Nielsen, P Rousselot, J Reiffers, G Saglio, P Shepherd, B Simonsson, A Gratwohl, JM Goldman, H Kantarjian, K Taylor, G Verhoef, AE Bolton, R Capdeville, BJ Druker: Imatinib compared with interferon and low dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348, 994-1004 (2003)
92. Shah NP, C Tran, FY Lee, P Chen, D Norris, CL Sawyers: Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305, 399-401 (2004)
93. Gorre ME, K Ellwood-Yen, G Chiosis, N Rosen, CL Sawyers: BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood 100, 3041-3044 (2002)
94. Branford S, Z Rudzki, S Walsh, I Parkinson, A Grigg, J Szer, K Taylor, R Hermann, JF Seymour, C Arthur, D Joske, K Lynch, T Hughes: Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 102, 276-183 (2003)
95. Löwenberg R: Minimal residual disease in chronic myeloid leukemia. N Engl J Med 349, 1399-1401 (2003)